Introduction

Joint wear is a common cause of pain and stiffness, arising from injury, age-related degeneration, or other conditions that affect articular cartilage. Because damaged joint surfaces recover poorly on their own, patients and clinicians are understandably interested in non-surgical options that may support the joint and reduce discomfort. This article explains how the ChondroFiller injection works in practice, with realistic expectations throughout.

What Makes the ChondroFiller Injection Non-Surgical?

ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold. When delivered as an injection, it requires no incision, no theatre, and no general anaesthetic. The clinician uses real-time ultrasound imaging to guide a fine needle precisely to the target area within the joint, then deposits the collagen gel at the correct site.

The gel is acellular — it contains no cells of its own — but is designed to be biocompatible and to recruit the patient's own progenitor cells from surrounding tissue over time. It self-gels within a few minutes of placement. Importantly, no healthy tissue is removed during the procedure. This distinguishes it from surgical approaches, which involve entering the joint through small portals (keyhole) or, in more extensive cases, an open incision.

A Step-By-Step Overview of the ChondroFiller Injection

The procedure is carried out as an outpatient appointment and typically follows a clear sequence.

1. Assessment and consent: the clinician reviews imaging, confirms the lesion location, and discusses the procedure and its realistic outcomes.
2. Preparation: the patient is positioned appropriately for the target joint. A local anaesthetic is administered to the skin and soft tissue if needed.
3. Ultrasound guidance: the clinician scans the joint with an ultrasound probe to confirm the needle entry point and visualise the target area in real time.
4. Injection: a fine needle is passed into the joint under continuous ultrasound view. The ChondroFiller scaffold is deposited at the worn or damaged surface.
5. Post-procedure: the needle is withdrawn. The patient is observed briefly, then given aftercare instructions and a follow-up plan.

The entire procedure is generally brief. Because it does not involve surgery, there is no surgical recovery period, and most patients return to light daily activities promptly. Responses to the treatment vary, and the experience of any individual cannot be guaranteed.

Patient Experience: Recovery and Expectations

The non-surgical nature of the ChondroFiller injection means that tissue trauma is minimal. There is typically little discomfort beyond mild soreness at the injection site, which usually settles within a day or two. Most people are able to return to everyday activities without extended rest, though clinicians may advise avoiding strenuous loading of the treated joint for a short period.

It is important to frame expectations correctly. ChondroFiller may support the joint environment and provide a layer that reduces surface-on-surface contact, but it is not a cure for cartilage loss, and it does not reverse established arthritis. The published literature, including the case series by Corain et al. (2023) in joints such as the trapeziometacarpal, suggests the approach can be associated with symptomatic improvement in appropriate patients — but outcomes vary.

Addressing Common Concerns

Many patients have questions about precision, discomfort, and whether such an injection can truly reach the right spot. Ultrasound guidance is central to addressing these concerns: unlike blind injections, it allows the clinician to see the needle position relative to the cartilage surface in real time, reducing the risk of incorrect placement.

Patients sometimes ask whether ChondroFiller is the same as the surgical procedure called Liquid Cartilage. They are distinct. The ChondroFiller injection described in this article is entirely non-surgical — an outpatient procedure using ultrasound guidance. Liquid Cartilage, by contrast, is a keyhole (arthroscopic) surgical protocol that delivers ChondroFiller alongside biological adjuncts such as platelet-rich fibrin or the patient's own mesenchymal stem cells. That surgical pathway is indicated for larger or load-bearing lesions and involves theatre, anaesthetic, and a structured recovery. A clinician will advise which pathway, if either, is appropriate after individual assessment.

Conclusion

The ChondroFiller injection offers a carefully planned, non-surgical approach to supporting a worn joint. Delivered under ultrasound guidance as an outpatient procedure, it involves no incision and no removal of healthy tissue. It is supportive rather than curative, and suitability varies by patient. For personalised advice on whether this or any other approach may be relevant to your joint, a specialist assessment is the appropriate starting point. At the London Cartilage Clinic, Harley Street, the team provides individual evaluation to help you understand your options clearly.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.

Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.